NYSEHealth CareMedical DevicesSnapshot 2026-07-23
Reading PEN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder in the healthcare sector. The current thesis state is intact, but recent changes indicate a mixed outlook due to earnings misses and sector performance.
PEN is currently considered expensive compared to its peers, with a significant premium. The market seems to have priced in a strong performance, but there is an expectations gap that suggests some uncertainty.
Management is focused on increasing revenue growth, which has shown positive results recently. However, there are concerns about maintaining gross margin guidance, and the company has a moderate risk profile due to recent earnings misses.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could support PEN's growth. Conversely, any negative guidance from these peers could impact PEN's momentum.
Overall, PEN's outlook remains cautiously optimistic, but it is important to monitor sector trends and management execution closely. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'mild_favorable'.
Mixed, the news cuts both ways. On one hand, Boston Scientific's focus on U.S. Thrombectomy growth reinforces Penumbra's market position. On the other hand, the latest earnings miss raises concerns about its performance.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: A drop below 15% would signal a slowdown in revenue growth, which is a key priority.
Confirms:Q2 revenue growth reported below 15% year over year.
Disproves:Q2 revenue growth remains at or above 15% year over year.
Why it matters: Earnings results will show if revenue growth is on track after the recent miss.
Confirms one read:Q2 revenue growth exceeds 10% year over year.
Confirms the other:Q2 revenue growth falls below 5% year over year.
Why it matters: Finishing the acquisition would support the company's plan. It could improve its market position.
Confirms:A press release will confirm the acquisition is done and approvals are received.
Disproves:News of delays or failure to finish the acquisition.
Why it matters: Growth here is very important for management. It also impacts total revenue growth.
Confirms:Management reports U.S. Thrombectomy revenue growth above 15% in the next update.
Disproves:U.S. Thrombectomy revenue growth remains below 5% in the next update.
Why it matters: If sector revenue growth drops, it may show bigger problems for Penumbra.
Confirms:Sector revenue growth has been below its average for two months in a row.
Disproves:Sector revenue growth is steady or goes above the average.
Why it matters: This shows that demand for Penumbra's main products is weakening. It could hurt growth.
Confirms:If Q2 thrombectomy revenue growth is reported below 10% year over year.
Disproves:If Q2 thrombectomy revenue growth remains above 10% year over year.
Why it matters: If it drops below this level, it may show cost issues. This could hurt profits.
Confirms:If gross margin is reported below 67.5% in upcoming quarters.
Disproves:If gross margin remains above 67.5% in upcoming quarters.
